拉伦综合征患者的残疾和障碍
1Schneider Children's Medical Center, Petah Tikva, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv-Yafo 6997801, Israel.
Children (Basel, Switzerland)
|September 27, 2025
概括
拉伦综合征 (LS) 是一种罕见的矮体,由不活跃的生长激素受体引起,导致严重的健康问题,如肥胖和糖尿病. 早期的IGF-I治疗可以预防和逆转这些衰弱症状,改善患者的生活质量.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 拉伦综合征 (LS) 是一种罕见的遗传矮体,与GH受体基因突变有关.
- 它导致不活跃的生长激素 (GH) 和低的胰岛素类生长因子I (IGF-I) 水平.
- 在全球范围内,LS影响着多样化的人口,在特定的种族群体中出现了显著的事件.
研究的目的:
- 记录拉伦综合征患者的各种残疾和障碍.
- 分析LS对从婴儿期到成年期的患者的影响.
- 评估IGF-I缺乏的长期后果.
主要方法:
- 76名拉伦综合征患者的纵向研究.
- 评估成长,社会成就和生活困难.
- 随着时间的推移,对体质和生化变化的监测.
主要成果:
- 长期存在的IGF-I缺乏会导致包括矮体,肥胖,糖尿病,脂肪肝和心血管问题在内的渐进性残疾.
- 神经和骨科问题很常见,影响职业培训,职业和社会生活.
- 这些并发症显著降低了LS患者的生活质量 (QoL).
结论:
- 早期的IGF-I替代疗法对于管理拉伦综合征至关重要.
- 早期开始治疗可以预防和逆转IGF-I缺乏症的症状.
- 及时干预可以改善患者的治疗结果和生活质量.
相关概念视频
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Learning Disabilities
575
Learning disabilities are cognitive disorders caused by neurological impairments that affect cognitive functions like language and reading, without indicating overall intellectual or developmental challenges. These disabilities differ from global intellectual or developmental disabilities as they are limited to distinct cognitive functions. Common learning disabilities include dysgraphia, dyslexia, and dyscalculia, each of which impacts unique aspects of learning.
Dyslexia
Dyslexia is a...
Dyslexia
Dyslexia is a...
575
Inborn Errors of Metabolism
697
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
697
Intellectual Disability
641
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
641
Glucose Transporters
27.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256


